Back

Volume 37 , Issue 2
March/April 2017
Pages 219–225

The Use of Recombinant Human Platelet-Derived Growth Factor for Maxillary Sinus Augmentation

Atsushi Kubota, DDS, PhD/Hector Sarmiento, DMD, MSc/Mohammed Saad Alqahtani/Arturo Llobell, DDS, MSc/Joseph P. Fiorellini, DMD, DMSc

PMID: 28196162
DOI: 10.11607/prd.2776

The maxillary sinus augmentation procedure has become a predictable treatment to regenerate bone for implant placement. The purpose of this study was to evaluate the effect of recombinant human platelet-derived growth factor BB (rhPDGF-BB) combined with a deproteinized cancellous bovine bone graft for sinus augmentation. The lateral window approach was used for maxillary sinuses with minimal residual bone. After a healing period of 4 months, dental implants were placed and then restored following a 2-month osseointegration period. The result demonstrated increased bone height and ISQ values and a 100% survival rate. This study indicates that the addition of rhPDGF-BB to deproteinized cancellous bovine bone accelerated the healing period in maxillary sinuses with minimal native bone.

Full Text PDF File | Order Article

 

 

Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.